Denali Therapeutics (DNLI) Stock: Buy, Sell, or Hold?
DNLI - Denali Therapeutics Inc. Common Stock
$21.09
-0.31 (-1.45%)
▼
5d:
-7.5%
30d:
-16.54%
90d:
+0.33%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DNLI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DNLI shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $21.09, which is considered oversold relative to its 30-day fair value range of $22.68 to $25.13.
Technical Outlook: Technically, DNLI is in a strong uptrend. The price is currently testing key support at $21.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DNLI scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.75 (+69.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DNLI is in a strong uptrend. The price is currently testing key support at $21.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DNLI scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $35.75 (+69.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$22.68 -
$25.13
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 69.5% below Wall St target ($35.75)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$22.68 -
$25.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$21.06
Resistance Level
$24.62
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.67
Wall Street Target
$35.75
(+69.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 13, 2026 3:18 PM ET
Data refreshes hourly during market hours. Next update: 4:18 PM
Data refreshes hourly during market hours. Next update: 4:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$314 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
